Jurkat Reporter Cell Lines for Immunotherapy Drug Screening
WuXi AppTec offers Jurkat reporter cell lines for immunotherapy drug screening. Our platform includes CD8+, TCR knockout and CD16-expressing Jurkat-NFAT-Luc reporter cell lines, and validated assays (using co-cultures of Raji or A375 tumor cells) to evaluate the activity of CARs, TCRs, and bispecific antibodies. Leverage our portfolio of reporter cell lines to accelerate your research!
Learn more about our platform of cell-based phenotypic assays by clicking HERE.
Jurkat reporter cell lines for immunotherapy drug screening
Related Content
Despite the success of delivery technologies such as lipid nanoparticles and trivalent GalNAc conjugation, targeted delivery of oligonucleotides to extra...
VIEW RESOURCEWuXi AppTec scientists contributed to a research article in the journal Translational Medicine Communications which characterized the antitumor immune responses...
VIEW RESOURCE